Morphologic, phenotypic, and transcriptomic characterization of classically and alternatively activated canine blood-derived macrophages \textit{in vitro}

Franziska Heinrich\textsuperscript{1,2}, Annika Lehmbecker\textsuperscript{1,2}, Barbara B. Raddatz\textsuperscript{1,2}, Kristel Kegler\textsuperscript{1,2}, Andrea Tipold\textsuperscript{2,3}, Veronika M. Stein\textsuperscript{2,4}, Arno Kalkuhl\textsuperscript{5}, Ulrich Deschl\textsuperscript{5}, Wolfgang Baumgärtner\textsuperscript{1,2,*}, Reiner Ulrich\textsuperscript{1,6}, Ingo Spitzbarth\textsuperscript{1,2}

\textsuperscript{1} Department of Pathology, University of Veterinary Medicine Hannover Foundation, Bünteweg 17, Hannover, Germany, \textsuperscript{2} Center for Systems Neuroscience, Bünteweg 2, Hannover, Germany, \textsuperscript{3} Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover Foundation, Bünteweg 2, Hannover, Germany, \textsuperscript{4} Department of Clinical Veterinary Sciences, Vetsuisse Faculty, University of Bern, Laenggassstrasse 128, Bern, Switzerland, \textsuperscript{5} Boehringer Ingelheim Pharma GmbH & Co.KG, Department of Non-clinical Drug Safety, Birkendorfer Str. 65, Biberach, Germany, \textsuperscript{6} Friedrich-Loeffler-Institute, Department of Experimental Animal Facilities and Biorisk Management, Südufer 10, Greifswald, Germany

* Wolfgang.Baumgaertner@tiho-hannover.de

Abstract

Macrophages are a heterogeneous cell population playing a pivotal role in tissue homeostasis and inflammation, and their phenotype strongly depends on the micromilieu. Despite its increasing importance as a translational animal model for human diseases, there is a considerable gap of knowledge with respect to macrophage polarization in dogs. The present study comprehensively investigated the morphologic, phenotypic, and transcriptomic characteristics of unstimulated (M0), M1- (GM-CSF, LPS, IFN\textsubscript{\gamma}-stimulated) and M2- (M-CSF, IL-4-stimulated)-polarized canine blood-derived macrophages \textit{in vitro}. Scanning electron microscopy revealed distinct morphologies of polarized macrophages with formation of multinucleated cells in M2-macrophages, while immunofluorescence employing literature-based prototype-antibodies against CD16, CD32, iNOS, MHC class II (M1-markers), CD163, CD206, and arginase-1 (M2-markers) demonstrated that only CD206 was able to discriminate M2-macrophages from both other phenotypes, highlighting this molecule as a promising marker for canine M2-macrophages. Global microarray analysis revealed profound changes in the transcriptome of polarized canine macrophages. Functional analysis pointed out that M1-polarization was associated with biological processes such as “respiratory burst”, whereas M2-polarization was associated with processes such as “mitosis”. Literature-based marker gene selection revealed only minor overlaps in the gene sets of the dog compared to prototype markers of murine and human macrophages. Biomarker selection using supervised clustering suggested \textit{latexin} (LXN) and \textit{membrane-spanning 4-domains, subfamily A, member 2} (MS4A2) to be the most powerful predicting biomarkers for canine M1- and M2-macrophages, respectively. Immunofluorescence for both markers demonstrated expression of both proteins by macrophages \textit{in vitro} but failed to reveal differences between canine M1 and M2-macrophages. The present study provides a solid basis for...
Introduction

Circulating peripheral blood mononuclear cells (PBMCs) play an important role during both the steady state and inflammation. Monocytes, which originate from hematopoietic stem cells, are capable of migrating from the blood into distinct tissues and differentiate into macrophages in order to replenish specific tissue-specific macrophage populations [1]. Functional diversity and plasticity are hallmarks of macrophages [2, 3]. Together they represent a heterogeneous cell population of the mononuclear phagocyte system playing a pivotal role in tissue homeostasis, inflammation, host defense, and tissue repair [4, 5]. Depending on the micromilieu, two extremes of macrophage phenotypes have been described following external or endogenous stimulation: “classically” activated M1-macrophages and “alternatively” activated M2-macrophages [6, 7]. Classically activated M1-macrophages develop after exposure to pro-inflammatory stimuli such as interferon γ (IFNγ), lipopolysaccharide (LPS), or tumor necrosis factor (TNF). Subsequent to such stimulation, M1-macrophages release pro-inflammatory cytokines, reactive oxygen species (ROS), and nitric oxide (NO) [8]. Hence, on the functional level, M1-macrophages are characterized by an increased microbicidal, tumoricidal, and antigen presenting capacity [2, 4, 9]. In contrast, M2-macrophages become activated in the presence of interleukin (IL)-4, IL-10, IL-13, glucocorticoids, and transforming growth factor β (TGFβ) leading to enhanced secretion of anti-inflammatory cytokines. Accordingly, M2-macrophages are functionally associated with hypersensitivity, parasite clearance, inflammatory dampening, tissue remodeling, angiogenesis, immunoregulation, and tumor promotion [2, 9, 10]. However, it should be taken into consideration that the M1-/M2–paradigm is a simplified classification, representing only two extremes of phenotypes which do not fully mirror the complexity of the dynamic biological processes behind cell polarization [7]. Hence, gene expression profiling has been applied as a sophisticated technique to detect the underlying molecular mechanisms following macrophage activation in murine and human cells [11–14]. In fact, macrophage activation by any agonist involves a massive change in gene expression during the transition from one steady state to another [5]. Notably, current comparative studies strongly support the observation of marked interspecies differences and variability between mice and humans indicating that about 50% of polarization specific markers are selectively expressed in only one of both species [13, 14].

Currently, spontaneous diseases in dogs play an established and increasing role as suitable animal models for human disorders including for instance demyelinating central nervous system (CNS) diseases, measles, cancer, and spinal cord injury (SCI) [15–21]. Conclusively, dogs represent a promising so called large animal model in the development of novel therapeutic approaches for naturally occurring diseases. However, despite the essential role of dogs as a translational animal model, there is a considerable lack of knowledge of the role of macrophage polarization in this species, and morphologic, phenotypic, and transcriptomic properties of polarized canine macrophages are enigmatic so far. However, a detailed knowledge of these basic principles doubtlessly represents a prerequisite for envisaged pharmacotherapeutic and cell transplantation studies.

Therefore, this in vitro study aimed to (i) characterize morphological differences of polarized canine macrophages, (ii) to test the capability of established murine and human prototypical markers to differentiate canine M1- and M2-macrophages using immunofluorescence,
and (iii) to unravel differences in the transcriptome of canine polarized macrophages using microarray technique in order to establish unique gene signatures, which differentiate these polarization states.

The presented results provide a highly needed basis for future research upon canine spontaneous diseases such as SCI and distemper leukoencephalitis with a special emphasis upon the so far enigmatic role of macrophage polarization in these diseases.

**Materials and methods**

**Blood cell isolation**

Blood samples were collected from a total number of 12 healthy Beagle dogs, which were kept in regulatory approved animal housing facilities of the Departments of Small Animal Medicine and Surgery and the Institute for Parasitology, University of Veterinary Medicine, Hannover, Germany. Blood collection was done by professional veterinarians from non-anesthetized dogs following the regulations of the German Animal Welfare Law and with permission provided by the Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit, Oldenburg, Germany (permission number: AZ33.9-42502-05-13A303). Following a clinical examination of each animal, which included auscultation of the lung and heart, and rectal measurement of the body temperature, the puncture spot was disinfected. A volume of 20 ml blood was collected from the cephalic vein of each dog. Following blood collection, local manual pressure was used to avoid bleeding. No animals were euthanized for the present study.

Peripheral blood mononuclear cells (PBMCs) were isolated via density gradient centrifugation using a routine protocol as described previously [22]. Briefly, blood samples were diluted 1:3 in phosphate buffered saline (PBS) containing 1% penicillin/streptomycin (Biochrom GmbH, Berlin, Germany) and added onto a gradient with equal volumes of histopaque 1.077 g/ml and 1.119 g/ml (Sigma Aldrich, Taufkirchen, Germany). After 30 minutes of centrifugation, cells were harvested using a Pasteur pipette, washed with PBS and 1% penicillin/streptomycin followed by depletion of erythrocyte contamination by hypotone lysis with distilled water. Subsequently, cells were resuspended in Roswell Park Memorial Institute (RPMI)-medium 1640 (Biochrom GmbH, Berlin, Germany) containing 10% fetal calf serum (PAA, Cölbe, Germany) and 1% penicillin/streptomycin and seeded onto 96-well plates (Thermo Scientific, Waltham, MA, USA) at a density of 0.3 x 10^6 cells/well. After 24 hours of cultivation under standard conditions (5% CO₂, 37°C), medium was completely removed and cells were washed twice with PBS and 1% penicillin/streptomycin. Cells attached to the base of wells with strong plastic adherence were referred to as monocytes [23–26].

**Cell culture and polarization**

To culture canine macrophages in vitro from blood-derived monocytes, a protocol according to Durafourt et al. (2012) [27] was used with slight modifications. Briefly, canine monocytes were cultured over 7 days towards M1-/M2-macrophages by stimulation with hematopoietic growth factors over 5 days followed by activation over 2 days with distinct cytokines, purchased from companies that guarantee an endotoxin level below 0.1 EU/μg of protein. In particular, to obtain M1-macrophages, monocytes were treated with 5 ng/ml canine recombinant granulocyte macrophage colony-stimulating factor (GM-CSF; R&D Systems, Minneapolis, MN, USA), 100 ng/ml LPS (Sigma Aldrich, Taufkirchen, Germany), and 20 ng/ml recombinant canine IFNγ (Kingfisher Biotech Inc., Saint Paul, Minnesota, USA). M2-macrophages were developed by treatment with 25 ng/ml human macrophage colony-stimulating factor (M-CSF, PeproTech Inc., Rocky Hill, NJ, USA) and 20 ng/ml canine recombinant IL-4 (R&D Systems, Minneapolis, MN, USA). Serving as a control, unstimulated monocytes were cultured...
under the same conditions with medium change every second day (M0-macrophages). After 7
days of cultivation, morphology, phenotype, and transcriptomic changes of M0-, M1-, and
M2-macrophages were assessed. Pictures were taken with an inverted fluorescence microscope
(Olympus IX-70, Olympus, Optical Co GmbH, Hamburg, Germany).

The overall number of cells for each polarization was counted on at least 4 microscopic pic-
tures (200x magnification) of three individual dogs on day 7 in culture and the mean numbers
of cells per 200x field were compared using one-factorial ANOVA and post-hoc t tests applying
SPSS version 21 for windows (IBM Inc., Chicago, USA).

For quantification of cellular morphology, microphotographs were taken at 200x magnifi-
cation and the number of cells with a distinct morphologic appearance out of at least 100
randomly selected cells was counted for each polarization (M0, M1, M2). Here, 4 distinct mor-
phologic types were defined. In particular, cells with a cellular diameter ≤ 10 μm and absent
cytoplasmic projections on the cellular surface were defined as small/roundish cells (morphol-
yogy 1); cells with a cellular diameter ≥ 10 μm and numerous cytoplasmic processes were
defined as amoeboid (morphology 2); cells obtaining an elongated bipolar morphology were
classified as spindeloid (morphology 3); and cells possessing a large, round, and flattened mor-
phology with a cellular diameter ≥ 30 μm and > 1 nuclei were classified as multinucleated
giant cells (MNGs; morphology 4).

The percentage of each of the four different morphologies was calculated in M0-, M1-, and
M2-macrophages from 3 animals. A mixed ANOVA with post-hoc alpha adjustment (Tukey-
Kramer) and significance level at p ≤ 0.05 was performed using the statistical software pro-
gramme SPSS version 21 for windows (IBM Inc., Chicago, USA) in order to compare the per-
centages of each of the morphologies between M0-, M1-, and M2-macrophages. Graphical
compilation was done with GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, USA).

Scanning electron microscopy
M0-, M1-, and M2-macrophages were prepared for representative ultrastructural characteriza-
tion using scanning electron microscopy as described previously [28]. Briefly, cells were fixed
in 2.5% glutaraldehyde/cacodylate buffer, post-fixed in 1% osmium tetroxide, and dehydrated
in a graded series of alcohol. Subsequently, cells were dried under a Critical Point Dryer
(E3000, Polaron, London, UK), and sputter-coated with gold, and examined under a digital
scanning electron microscope (DSM 940, Zeiss, Oberkochen, Germany). At least 50 cells were
photographed for each morphology and evaluated with regard to ultrastructural morphology.

Immunocytochemistry
Immunolabelling of canine M0-, M1-, and M2-macrophages from 5 individuals was per-
formed using a routine protocol described previously [29, 30]. A panel of different literature-
based prototype marker antibodies, reported to distinguish between M1- and M2-macro-
phages was applied (Table 1; [4, 31]). Briefly, cells were fixed with paraformaldehyde (PFA,
4%) for 20 minutes at room temperature (RT) and permeabilized with Triton X (0.25%)
diluted in PBS (PBST). Non-specific binding was blocked by treatment of cells with bovine
serum albumin (BSA, 3%; Sigma Aldrich, Taufkirchen, Germany) and normal goat serum
(5%) diluted in PBST for 15 minutes at RT, except for cells intended to be stained with anti-
odies directed against Fc-receptors, i.e. CD16 and CD32. Subsequently, primary antibodies
(Table 1) were added and incubated for 2 hours at RT. All unconjugated primary antibodies
were labeled with secondary goat-anti-mouse antibodies coupled to cyanine 3 (Cy3), goat-
anti-rat antibodies coupled to Cy2, and goat-anti-rabbit antibodies coupled to Cy3 (all
received from Jackson ImmunoResearch Laboratories, Dianova, Hamburg, Germany; dilution
1:200 in PBS), respectively, and incubated for 2 hours at RT. Following appropriate washing steps with PBS and distilled water, nuclei were counterstained with bisbenzimide (H33258, 0.01% in distilled water) for 5 minutes at RT. Species-specific immunoglobulins from mouse, rat, goat, and rabbit diluted according to the immunoglobulin concentration of the primary antibodies served as appropriate negative controls. M0-, M1-, and M2-macrophages were investigated using an inverted fluorescence microscope (Olympus IX-70, Olympus, Optical Co GmbH, Hamburg, Germany). For quantification of immunopositivity, microphotographs were taken at 200x magnification and at least 100 randomly selected cells were counted for each treatment (M0, M1, M2) with respect to the number of immunopositive cells and the total number of cells. Statistical comparison of the percentage of immunopositive cells between M0-, M1-, and M2-macrophages was done using a Kruskal-Wallis-Test and pairwise Mann-Whitney-U-Tests with significance level at p ≤ 0.05 employing the statistical software programme SPSS version 21 for windows, and box plots were depicted using GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, USA).

Based on the results of the transcriptome investigations (see below), two additional antibodies targeting LXN and MS4A2 (Table 1) were applied on isolated and polarized cells of 3 dogs. Immunofluorescence was performed analogously to the above mentioned methods. For these antibodies, blocking was done with normal horse serum. Donkey-anti-goat and donkey-anti-rabbit antibodies were used as secondary antibodies. Due to the lower n (3 dogs), statistical comparison of the percentage of immunopositive cells between M0-, M1-, and M2-macrophages was done using parametrical tests (one-factorial ANOVA and pairwise t tests) for these both antibodies.

### RNA isolation, microarray hybridization, and low level analysis

For RNA-isolation a separate and analogous in vitro experiment was performed using blood-derived cells from 6 healthy Beagles. Total RNA was isolated from 6 biological replicates of
M0-, M1- and M2- macrophages using the RNeasy Mini Kit according to the manufacturer’s instructions (Qiagen, Hilden, Germany). Quality and integrity of isolated RNA were controlled using the Agilent 6000 RNA Nano Kit and an Agilent Bioanalyzer 2100 (Agilent, Böblingen, Germany). 200 ng RNA of each sample was amplified and biotin-labeled employing the Ovation RNA Amplification Kit V2 and the Encore Biotin Module (NuGen, San Carlos, USA), and hybridized to GeneChip Canine Genome 2.0 arrays (Affymetrix, Santa Clara, USA) in a rotating oven (45˚C, 16 hours). Subsequently, arrays were washed and stained with R-phycoerythrin-streptavidin employing Affymetrix GeneChip Fluidics Station 450 (Affymetrix, Santa Clara, USA). For scanning, an Affymetrix GeneChip Scanner 3000 (Affymetrix, Santa Clara, USA) was employed for signal detection. Background adjustment, quantile normalization, and probe-set summarization were performed using the Gene Chip Robust Multi-chip Average (GC-RMA) algorithm (Bioconductor gcrma for R package, Version 2.3) as previously described [32]. Raw and processed data sets of the present study are deposited and publically available in the ArrayExpress database (accession number: E-MTAB-5458; http://www.ebi.ac.uk/arrayexpress).

Differentially expressed probe sets

Differentially expressed probe sets (DEPs) were detected using the Linear Models for Microarray Data (LIMMA) algorithm, implemented in Babelomics 4.3 (http://babelomics.bioinfo.cipf.es; [33]), with a maximal false discovery rate (FDR) of 5% (q≤0.05) according to Benjamini and Hochberg, followed by post-hoc pairwise comparison of the expression levels of M0-, M1-, and M2-macrophages [32, 34]. The fold change (FC) was calculated as the ratio of the inverse-transformed arithmetic means of the log2-transformed expression values. Down-regulations are shown as negative reciprocal values [34, 35]. Probe sets were annotated with canine gene symbols and gene names according to the Affymetrix annotation file (release 35; 06. October 2014). A statistical significance filter (LIMMA q≤0.05) and a fold change filter (FC≥2.0 or ≤-2.0) were employed to identify differentially expressed probe sets (DEPs) [32]. Differentially expressed genes (DEGs) were defined as probe sets with a unique canine gene symbol annotation [36].

Functional annotation and hierarchical clustering analysis

Functional enrichment analysis of the DEPs for overexpressed Gene Ontology (GO) terms of the biological process category and the Kyoto encyclopedia of genes and genomes (KEGG) was performed using Web-based Gene Set Analysis Toolkit (WebGestalt; http://bioinfo.vanderbilt.edu/webgestalt/; [37–39]). In order to detect the genes in the pairwise comparison of M0-, M1-, and M2-macrophages, whose expression was most severely affected, genes with a FC≥50.0 or ≤-50.0 were selected and grouped into biological categories [36]. Moreover, unsupervised hierarchical clustering analysis of the DEPs was performed on log2-transformed data using TM4 MultiExperimentViewer (MeV) with default settings (Euclidean distance and complete linkage) [40]. The list of DEPs for each of the resulting clusters was functionally analyzed for significant enrichment applying WebGestalt as described above.

Correlation-based marker gene selection

Based on the transcriptional profile, a subset of probe sets for polarization prediction was selected using Prophet [41], provided by Babelomics 4.3 [33, 42]. Correlation-based feature selection was used to pre-select the informative subset of probe sets and K-nearest-neighbors (KNN) algorithm was used for class prediction with leave-one out error validation [42]. The
informative subset of 369 probe sets derived from Prophet was further analyzed for the polarization prediction strength of each individual probe set in three independent “M0 versus M1 and M2”, “M1 versus M0 and M2”, and “M2 versus M0 and M1” tests using Signature evaluation tool (SET; [42, 43]). The log$_2$-transformed expression values of three biomarkers, suggested by Prophet, were additionally statistically compared between M0-, M1-, and M2-macrophages, employing Kruskal-Wallis-Test and subsequent pairwise Mann-Whitney-U-Tests with significance value $p \leq 0.05$.

Comparative evaluation of canine M1-/M2-genes with established literature-based human and murine orthologous genes

All unique gene symbols, which were up-regulated (FC$\geq$2; $q \leq 0.05$) in the comparison of M1 vs. M0 and simultaneously up-regulated in the comparison of M1 vs. M2 were defined as M1-exclusive-genes ($n$ = 404). Likewise, all unique gene symbols, which were up-regulated (FC$\geq$2; $q \leq 0.05$) in the comparison of M2 vs. M0 and simultaneously up-regulated in the comparison of M2 vs. M1 were defined as M2-exclusive-genes ($n$ = 700). The gene sets of these exclusive M1- or M2-associated canine genes were compared with a list of established human and murine genes specifically associated with M1- or M2-macrophages. This list was generated based on peer-reviewed publications [4, 27, 31, 44] as previously described [8, 45]. This list was translated into canine orthologous gene symbols by employing MADgene (http://cardioserve.nantes.inserm.fr/madtools/madgene/; [46]) and missing orthologous canine official gene symbols were manually added with the help of the web-based “information hyperlinked over proteins” (ihop; http://www.ihop-net.org/UniPub/iHOP/; [47]) as described previously [36]. Summarized, the literature-based gene list included a total number of 65 orthologous canine genes for M1-macrophages and 58 orthologous canine genes for M2-macrophages [36]. Venn diagrams (http://bioinfogp.cnb.csic.es/tools/venny/index.html) were used to reveal the intersections between established literature-based genes and the gene sets identified by the present analysis.

Results

Morphological characterization of polarized canine macrophages

On day 7 in culture, the overall number of cells differed between the three polarities ($p = 0.02$; S1 Fig). The number of cells was highest in M2-polarized cells (mean = 135 cells per field), while M0-macrophages were lowest in number (mean = 30 cells per field). M1-macrophages had a mean number of 52 cells per field. T tests revealed that the number of M2-macrophages was significantly higher than M0-macrophages ($p = 0.02$), while comparisons between M0- and M1-macrophages and M1-and M2-macrophages failed to reach the level of significance ($p = 0.30$ and $p = 0.06$, respectively).

Morphologically, striking differences between M0-, M1-, and M2-polarized cells were observed at day 7 in culture by scanning electron microscopy and phase contrast microscopy (Fig 1). Canine M0-macrophages predominantly appeared as small and roundish cells with an average size of 8 $\mu$m in diameter and no or little cytoplasmic extensions that measured up to 1 $\mu$m in length (Fig 1). However, a noteworthy proportion of M0-macrophages (about 25%) also obtained an amoeboid morphology, which however was predominantly observed in M1 macrophages (Fig 1). The majority of M1-macrophages was amoeboid and had a mean size of 15 $\mu$m and numerous fibrillary cytoplasmic processes on the cellular surface that had a length of up to 5 $\mu$m (Fig 1). M2-macrophages appeared as a heterogeneous cell population with a mixture of 4 different morphologies. Besides roundish and amoeboid macrophages, large...
bipolar spindleoid macrophages were present measuring up to 35 μm that were characterized by an elongated cell body with cytoplasmic extensions at both poles (Fig 1). Moreover, large MNGs appeared that had a mean size of 40 μm with an extensive cytoplasm and numerous evenly distributed processes that measured up to 7 μm (Fig 1). Overall, the mean percentage of small/roundish macrophages (morphology 1) was significantly higher in untreated cultures (M0) compared to polarity 2 at days 5 and 7 (p<0.05; Fig 1E). For amoeboid macrophages (morphology 2), there was a trend towards a higher mean percentage in polarity 1 compared to polarity 0 at day 5 (p = 0.07) and day 7 (p = 0.06; Fig 1F). The mean percentage of spindleoid macrophages (morphology 3) was significantly higher in polarity 2 at day 5 compared to polarity 1 at day 5 (p<0.05; Fig 1G). MNGs (morphology 4) were exclusively present in M2 macrophages at the end of the culturing period and their percentage is significantly higher at day 7 in M2 compared to both M0 and M1.

Phenotypical characterization of polarized canine macrophages

For the phenotypical characterization of canine macrophages, the percentage of immunopositive cells for selected literature-based M1-/M2-antigens was evaluated in 5 animals and related to the polarization of cells (polarity 0, 1, 2). Interestingly, except for MHC class II and CD206, none of the remaining tested antigens (CD16, CD32, iNOS, CD163, and arginase-1) were differentially expressed between canine M0-, M1-, and M2-macrophages (p-values ranging from 0.101 to 0.691; Kruskal-Wallis-Test; Fig 2).
The mean percentage of immunopositive cells expressing MHC class II was significantly higher in M2-macrophages (mean positive cells: 93.64%) when compared to untreated M0-cells (mean positive cells: 72.22%; p = 0.008). However, there was no statistical difference in the percentage of positive cells for MHC class II, when M1-macrophages (mean positive cells: 89.92%) were compared to M2-macrophages and M0-macrophages, respectively (Fig 2).

For CD206, the mean percentage of immunopositive cells was highest in M2-macrophages (mean: 66.54%) as compared to both M0-macrophages (mean: 33.33%; p = 0.008) and M1-macrophages (mean: 28.67%; p = 0.032, Fig 3). No statistical difference was observed between M1- and M0-macrophages (Fig 3). The results were validated in the microarray data set, which similarly revealed significantly higher expression levels of CD206 in canine M2-macrophages as compared to both M1- (p = 0.002) and M0-macrophages (p = 0.004; Fig 3).

**Differentially expressed genes between M0-, M1-, and M2-polarized macrophage cultures**

One-factorial multigroup analysis of microarray data and fold change criteria identified 6358 probe sets that were differentially expressed in at least one of the three post-hoc pairwise comparisons. The total number of DEPs was 3555 in M1 vs. M0, 4831 in M2 vs. M0, and 3141 in M2 vs. M1, respectively (Table 2). In all pairwise comparisons, the number of up- and down-regulated probe sets was nearly equally distributed (M1 vs. M0: 1699 up, 1856 down; M2 vs. M0: 2467 up, 2364 down; M2 vs. M1: 1572 up, 1569 down). Functional annotation of enriched biological processes in DEPs, up-regulated in the comparison M1 vs. M0, revealed terms for “organonitrogen compound metabolic process”, “carbohydrate metabolic process”, “carboxylic acid metabolic process”, and “tricarboxylic acid cycle” (Table 2). In contrast, biological terms in down-regulated DEPs in this comparison reflected terms for “positive regulation of immune response”, “immune response-regulating signaling pathway”, and “regulation of innate immune response”. In both comparisons M2 vs. M0 and M2 vs. M1, up-regulated DEPs displayed significantly enriched gene ontology terms for “M phase of mitotic cell cycle” and “mitotic spindle organization”. Additionally, in M2 vs. M0 comparison, up-regulated DEPs were associated with “oxidation-reduction process”, “carboxylic acid metabolic process”, and “organonitrogen compound metabolic process”, whereas down-regulated DEPs were related to the biological term “immune response-activating signal transduction”. In the comparisons M2 vs. M1, down-regulated DEPs were functionally associated to biological terms such as “response to other organism”, “defense response”, “regulation of lymphocyte activation”, and “regulation of immune response” (Table 2).

Enriched KEGG-pathways, significantly associated with up-regulated canine DEPs in M1 vs. M0 (1699 DEPs), were functionally related to “metabolic pathways”, “glutathione metabolism”, “steroid biosynthesis”, and “glycolysis/gluconeogenesis”. The comparison M2 vs. M0 (2467 up-regulated DEPs) contained enriched KEGG-pathways for “metabolic pathways”,
“glycolysis/gluconeogenesis”, “propanoate and pyruvate metabolism”, “steroid biosynthesis”, and “cell cycle”. In the comparison M2 vs. M1 (1572 up-regulated DEPs), enriched KEGG-pathways included terms for “cell cycle”, “metabolic pathways”, “ribosome biogenesis in eukaryotes”, and “PPAR signaling pathway”. In contrast, down-regulated DEPs in the three comparisons were associated with “hematopoietic cell lineage”, “RIG-I-like receptor signaling pathway”, “T cell receptor signaling pathway”, and “cell adhesion molecules” (M1 vs. M0), “T cell receptor signaling pathway”, “natural killer cell mediated cytotoxicity”, and “hematopoietic cell lineage” (M2 vs. M0), and “NOD-like receptor signaling pathway”, “osteoclast differentiation”, “Toll-like receptor signaling pathway”, and “B and T cell receptor signaling pathway” (M2 vs. M1; Table 2).

Genes whose expression was most severely affected (FC ≥50.0 or ≤-50.0) in the pairwise comparison are depicted in Tables 3, 4 and 5. Fortynine genes fulfilled these filtering criteria in the M1 vs. M0 contrast (25 up, 24 down), whereas 99 genes were retrieved in the comparison of M2 vs. M0 (41 up; 58 down). Comparing M2 with M1, 66 genes fulfilled the criteria (32 up; 34 down). Focusing on potentially promising cell surface markers, the pairwise comparison of three genes encoding for such surface molecules were up-regulated in M1 vs. M0, namely SUCNR1, SDC4, and CHRNA9, whereas CD209, CD180, KLRG1, COLEC12, and C3AR1 were
down-regulated (Table 3). Comparing M2 vs. M0, nine cell surface makers were up-regulated, i.e. **LYVE1, SUCNR1, CD1e, MRC1, TSPAN7, JAM3, ANTXR1, MS4A2, and CLEC4G** (Table 4). In contrast, a total amount of 18 cell surface marker genes was down-regulated, namely **ITGB8, LY6E, TRDC, NCR3, SELL, SIGLEC1, KLRD1, KLRB1, MMP6, P2RY14, TRBC2, TARP, FCRLA, KCNK5, P2RX5, NKG7, CD69, and CD7** (Table 4). In the comparison M2 vs. M1, the up-regulated cell surface marker genes contained 10 terms for **FCER1A, CD209, LYVE1, CLEC4G, COLEC12, JAM3, MS4A2, STAB1, MRC1, and SLC15A1** (Table 5). Down-regulated cell surface marker genes were **P2RY14, SLC39A14, ITGB8, TMEM150C, TMEM176A, and SLC22A15** (Table 5).

Interestingly, gene expression of **CD209** markedly decreased in the pairwise comparison of M1 vs. M0 (FC = -345.12) whereas it was highly up-regulated in the comparison M2 vs. M1 (FC = 335.12). In both comparisons, M2 vs. M0 and M2 vs. M1, genes for **LYVE1, MRC1, MS4A2, JAM3, and CLEC4G** were up-regulated, whereas genes for **ITGB8 and P2RY14** were down-regulated. **SUCNR1** was up-regulated in both M1 vs. M0 and M2 vs. M0.

Table 2. Summarized results of the functional annotation of the pairwise comparisons of differentially expressed probe sets (DEPs) in canine M0-, M1-, and M2-macrophages.

| Pairwise comparison | Differentially expressed probe sets | Up-/down-regulated probe sets | Enriched biological process categories* | Enriched KEGG pathways* |
|---------------------|-------------------------------------|--------------------------------|---------------------------------------|------------------------|
| M1 vs. M0           | 3555                                | Up: 1699                       | • Organonitrogen compound metabolic process  
                        |                                     | Down: 1856                     | • Positive regulation of immune response  
                        |                                     |                                 | • Immune response-regulating signaling pathway  
                        |                                     |                                 | • Regulation of innate immune response  
                        |                                     |                                 | • Hematopoietic cell lineage  
                        |                                     |                                 | • RIG-I-like receptor signaling pathway  
                        |                                     |                                 | • T cell receptor signaling pathway  
                        |                                     |                                 | • Cell adhesion molecules  |
| M2 vs. M0           | 4831                                | Up: 2467                       | • Oxidation-reduction process  
                        |                                     | Down: 2364                     | • Immune response-activating signal transduction  
                        |                                     |                                 | • T cell receptor signaling pathway  
                        |                                     |                                 | • Natural killer cell mediated cytotoxicity  
                        |                                     |                                 | • Hematopoietic cell lineage  |
| M2 vs. M1           | 3141                                | Up: 1572                       | • Mitotic spindle organization  
                        |                                     | Down: 1569                     | • Response to other organism  
                        |                                     |                                 | • Defense response  
                        |                                     |                                 | • Regulation of lymphocyte activation  
                        |                                     |                                 | • Regulation of immune response  
                        |                                     |                                 | • NOD-like receptor signaling pathway  
                        |                                     |                                 | • Osteoclast differentiation  
                        |                                     |                                 | • Toll-like receptor signaling pathway  
                        |                                     |                                 | • B and T cell receptor signaling pathway  |

* employing Web-based Gene Set Analysis Toolkit (WebGestalt; http://bioinfo.vanderbilt.edu/webgestalt/) with default settings  
adjusted p-value < 0.05

https://doi.org/10.1371/journal.pone.0183572.t002
Table 3. List and subgrouping of the top hits of highly differentially expressed genes (fold change $\geq 50$ or $\leq -50$) in canine M1- vs. M0-macrophages.

| Gene name                                      | Gene symbol | Fold change |
|------------------------------------------------|-------------|-------------|
| **Up-regulated genes**                         |             |             |
| **Cell surface markers**                       |             |             |
| Succinate receptor 1                           | SUCNR1      | 212.94      |
| Syndecan 4                                     | SDC4        | 58.61       |
| Cholinergic receptor, nicotinic, alpha 9 (neuronal) | CHRNA9     | 53.74       |
| **Enzymes**                                    |             |             |
| ADP-ribo-sylhydrolase like 2                   | ADPRHL2     | 535.59      |
| Ceruloplasmin (ferroxidase)                    | CP          | 161.88      |
| Epoxide hydrolase 2, cytoplasmic               | EPHX2       | 119.72      |
| Ectonucleotide pyrophosphatase/phosphodiesterase 2 | ENPP2     | 117.43      |
| Interstitial collagenase-like                  | LOC489428   | 87.83       |
| E3 ubiquitin-protein ligase NEURL3-like        | LOC102152163| 86.20       |
| NOP2/Sun domain family, member 7              | NSUN7       | 66.00       |
| Nucleoredoxin                                  | NNX         | 64.78       |
| WNK lysine deficient protein kinase 2          | WNK2        | 52.35       |
| **Cytokines, chemokines, and their Receptors** |             |             |
| Interleukin 6 (interferon, beta 2)             | IL6         | 252.32      |
| Chemokine (C-C motif) ligand 2                 | CCL22       | 187.96      |
| Chemokine (C-X-C motif) receptor 7             | ACKR3       | 178.18      |
| Interleukin 22 receptor, alpha 2               | IL22RA2     | 110.00      |
| Chemokine (C-X-C motif) ligand 14              | CXCL14      | 108.55      |
| Chemokine (C-C motif) ligand 17                | CCL17       | 95.26       |
| Chemokine (C-C motif) ligand 20                | CCL20       | 67.90       |
| **Soluble factors**                            |             |             |
| Chitinase 3-like 1 (cartilage glycoprotein-39) | CHI3L1      | 83.25       |
| Clusterin                                      | CLU         | 66.23       |
| **Miscellaneous**                              |             |             |
| Ras homolog family member U                    | RHOU        | 446.23      |
| Interferon, alpha-inducible protein 6          | IFI6        | 269.13      |
| CXADR-like membrane protein                    | CLMP        | 213.81      |
| Retinoic acid induced 14                       | RAI14       | 118.86      |
| **Down-regulated genes**                      |             |             |
| **Cell surface markers**                       |             |             |
| CD209 molecule                                 | CD209       | -345.12     |
| CD180 molecule                                 | CD180       | -75.00      |
| Killer cell lectin-like receptor subfamily G, member 1 | KLRG1     | -66.25      |
| Collectin sub-family member 12                 | COLEC12     | -61.81      |
| Complement component 3a receptor 1             | C3AR1       | -55.16      |
| **Enzymes**                                    |             |             |
| Carboxypeptidase M                             | CPM         | -134.50     |
| N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase) | NPL | -78.98 |
| Cathepsin E                                    | CTSE        | -76.30      |
| **Cytokines, chemokines, and their receptors** |             |             |
| Chemokine (C-X-C motif) ligand 12              | CXCL12      | -401.92     |
| Pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) | PPBP | -100.42    |
| Interleukin 2                                  | IL2         | -95.84      |

(Continued)
Hierarchical cluster analysis

Unsupervised hierarchical clustering analysis formed 9 different clusters based on similarities and differences in the expression profile of DEPs (Fig 4). Two out of these 9 clusters had an expression profile that was visually clearly associated with either the M1- or M2-phenotype (Fig 4). Functional annotation of these clusters identified that the M1-polarization cluster (cluster 8) was significantly associated with the biological process “respiratory burst involved in defense response” (Fig 4). The M2-cluster (cluster 6) was significantly associated with multiple biological processes of mitosis such as “M phase of mitotic cell cycle” and “mitotic spindle organization” (Fig 4). The genes associated with these M1- and M2-specific clusters are listed with their particular fold changes in S1 and S2 Tables. The remaining 7 clusters were neither specific for M1- nor for M2-macrophages and were associated with biological terms like “peptidyl-lysine mono- and dimethylation” (cluster 1), “immune response-activating signal transduction” (cluster 3), “monosaccharide metabolic process”, “organic substance catabolic process”, “cellular catabolic process” (cluster 4), “response to other organism”, “regulation of lymphocyte proliferation” (cluster 5), “tRNA aminoacylation for protein translation” (cluster 7), “cytokinesis” and “antigen receptor-mediated signaling pathway” (cluster 9, S3 Table). No significantly enriched biological terms were identified for cluster 2.

Literature-based gene signatures and marker genes

Intersections of genes exclusively up-regulated in M1 vs. M0 and down regulated in M2 vs. M1 (M1-macrophage genes), as well as genes up-regulated in the comparisons M2 vs. M0 and M2 vs. M1 (M2-macrophage genes) were selected and compared to literature-based markers that are known to distinguish between human and murine M1- and M2-macrophages (Fig 5A). Notably, many markers identified in the recent study to be specific for canine M1-polarization (404 unique genes in total corresponding to 565 probesets, S5 Table) did not match with the literature-based M1-markers (65 genes). Similarly, predominating numbers of canine M2-markers (700 unique genes in total corresponding to 1029 probesets, S5 Table) did not match with the literature-based M2-markers (58 genes; Fig 5A). However, overlapping expression of genes reflecting M1-polarization state was present for 8 genes, i.e. BIRC3, CCR7, CD80,

Table 3. (Continued)

| Gene name                                      | Gene symbol | Fold change |
|------------------------------------------------|-------------|-------------|
| Interleukin 1 receptor, type II               | IL1R2       | -79.71      |
| Chemokine (C-C motif) receptor 3              | CCR3        | -51.05      |
| **Soluble factors**                           |             |             |
| Lipocalin 2                                   | LCN2        | -180.73     |
| CD5 molecule-like                             | CD5L        | -153.48     |
| Secreted phosphoprotein 2, 24kDa              | SPP2        | -51.92      |
| **Miscellaneous**                             |             |             |
| Coagulation factor XIII, A1 polypeptide       | F13A1       | -3305.03    |
| Fatty acid binding protein 4, adipocyte       | FABP4       | -370.34     |
| G protein-coupled receptor 116                | GPR116      | -130.89     |
| Interferon-induced transmembrane protein 3-like | LOC606890  | -114.16     |
| Plexin domain containing 2                    | PLXDC2      | -67.07      |
| ADP-ribosylation factor-like 4C               | ARL4C       | -56.52      |
| Cyclin J-like                                 | CCNJL       | -54.76      |
| Thrombospondin 1                              | THBS1       | -53.38      |

https://doi.org/10.1371/journal.pone.0183572.t003
Table 4. List and subgrouping of the top hits of highly differentially expressed genes (fold change \( \geq 50 \) or \( \leq -50 \)) in canine M2- vs. M0-macrophages.

| Gene name                                      | Gene symbol | Fold change |
|------------------------------------------------|-------------|-------------|
| **Up-regulated genes**                         |             |             |
| **Cell surface markers**                       |             |             |
| Lymphatic vessel endothelial hyaluronan receptor 1 | LYVE1       | 322.32      |
| Succinate receptor 1                           | SUCNR1      | 151.91      |
| CD1e molecule                                  | CD1E        | 147.40      |
| Mannose receptor, C type 1                     | MRC1        | 104.41      |
| Tetraspanin 7                                  | TSPAN7      | 83.25       |
| Junctional adhesion molecule 3                 | JAM3        | 78.46       |
| Anthrax toxin receptor 1                       | ANTXR1      | 72.95       |
| Membrane-spanning 4-domains, subfamily A, member 2 | MS4A2      | 54.98       |
| C-type lectin domain family 4, member G        | CLEC4G      | 54.14       |
| **Enzymes**                                    |             |             |
| ADP-ribosylhydrolase like 2                    | ADPRHL2     | 614.52      |
| Guanine deaminase                              | GDA         | 174.44      |
| Ubiquitin-conjugating enzyme E2 C-like         | LOC481325   | 151.23      |
| Ribonucleotide reductase M2                    | RRM2        | 131.03      |
| Fructose-1,6-bisphosphatase 1                  | FBP1        | 57.95       |
| Matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) | MMP9    | 56.03       |
| Lipoprotein lipase                             | LPL         | 52.03       |
| Trimethyllysine hydroxylase, epsilon           | TMLH        | 51.05       |
| 3-hydroxybutyrate dehydrogenase, type 2        | BDH2        | 50.68       |
| **Cytokines, chemokines, and their receptors** |             |             |
| Chemokine (C-C motif) ligand 24                | CCL24       | 1060.82     |
| Chemokine (C-X-C motif) receptor 7             | ACKR3       | 390.67      |
| Chemokine (C-C motif) ligand 17                | CCL17       | 209.36      |
| Chemokine (C-C motif) ligand 13                | CCL13       | 172.58      |
| Interleukin 13 receptor, alpha 2               | IL13RA2     | 170.59      |
| Transforming growth factor, beta 2             | TGFB2       | 61.84       |
| **Soluble factors**                            |             |             |
| Nephronectin                                   | NPNT        | 444.07      |
| Norrie disease (pseudoglioma)                  | NDP         | 213.72      |
| Endothelin 1                                   | EDN1        | 115.81      |
| Cystatin 9 (testatin)                          | CST9        | 58.21       |
| **Miscellaneous**                              |             |             |
| Sodium channel, voltage-gated, type II, beta subunit | SCN2B | 1061.28     |
| Caldesmon 1                                    | CALD1       | 224.66      |
| CXADR-like membrane protein                    | CLMP        | 169.27      |
| SHC SH2-domain binding protein 1               | SHCBP1      | 117.77      |
| Dynamin 1                                      | DNMI        | 112.78      |
| NACC family member 2, BEN and BTB (POZ) domain containing | NACC2 | 110.49      |
| Retinoic acid induced 14                       | RAI14       | 84.35       |
| Scinderin                                      | SCIN        | 71.66       |
| Kinesin family member 23                       | KIF23       | 66.78       |
| Kinesin family member 11                       | KIF11       | 64.20       |
| Cfa-mir-125b-2                                 | cfa-mir-125b-2 | 58.78    |
| AHNNAK nucleoprotein                          | AHNNAK      | 57.19       |

(Continued)
Table 4. (Continued)

| Gene name                                                                 | Gene symbol | Fold change |
|---------------------------------------------------------------------------|-------------|-------------|
| NUF2, NDC80 kinetochore complex component                                  | NUF2        | 54.62       |

**Down-regulated genes**

**Cell surface markers**

| Cell surface markers                                                                 | Gene symbol | Fold change |
|-------------------------------------------------------------------------------------|-------------|-------------|
| Integrin, beta 8                                                                     | ITGB8       | -199.37     |
| Lymphocyte antigen 6 complex, locus E                                               | LY6E        | -116.70     |
| T cell receptor delta constant                                                      | TRDC        | -112.73     |
| Natural cytotoxicity triggering receptor 3                                           | NCR3        | -105.99     |
| Selectin L                                                                          | SELL        | -95.45      |
| Sialic acid binding Ig-like lectin 1, sialoadhesin                                  | SIGLEC1     | -91.39      |
| Killer cell lectin-like receptor subfamily D, member 1                              | KLRD1       | -87.12      |
| Killer cell lectin-like receptor subfamily B, member 1                              | KLRB1       | -74.56      |
| Membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6)                    | MPP6        | -72.60      |
| Purinergic receptor P2Y, G-protein coupled, 14                                      | P2RY14      | -71.69      |
| T cell receptor beta constant 2                                                     | TRBC2       | -64.26      |
| TCR gamma alternate reading frame protein                                           | TARP        | -62.39      |
| Fc receptor-like A                                                                  | FCRLA       | -60.06      |
| Potassium channel, subfamily K, member 5                                             | KCNK5       | -58.16      |
| Purinergic receptor P2X, ligand-gated ion channel, 5                                 | P2RX5       | -58.16      |
| Natural killer cell group 7 sequence                                                | NKG7        | -57.26      |
| CD69 molecule                                                                       | CD69        | -54.53      |
| CD7 molecule                                                                        | CD7         | -52.57      |

**Enzymes**

| Enzymes                                                                 | Gene symbol | Fold change |
|------------------------------------------------------------------------|-------------|-------------|
| Interferon stimulated exonuclease gene 20kDa                           | ISG20       | -514.04     |
| Prostaglandin E synthase                                               | PTGES       | -382.20     |
| Cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial               | CMPK2       | -266.50     |
| Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) | GZMA        | -131.27     |
| Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) | GZMB        | -130.63     |
| Hexokinase 3 (white cell)                                              | HK3         | -127.10     |
| Ubiquitin specific peptidase 18                                        | USP18       | -81.72      |
| Phospholipase A1 member A                                              | PLA1A       | -72.65      |
| Cathepsin E                                                           | CTSE        | -72.13      |
| GTP cyclohydrolase 1                                                  | GCH1        | -66.29      |
| Chymase 1, mast cell                                                  | CMA1        | -61.45      |
| Phospholipid scramblase 1-like                                         | LOC611500   | -61.09      |

**Cytokines, chemokines, and their receptors**

| Cytokines, chemokines, and their receptors                                | Gene symbol | Fold change |
|-------------------------------------------------------------------------|-------------|-------------|
| Chemokine (C-X-C motif) ligand 12                                        | CXCL12      | -417.05     |
| Interleukin 2                                                          | IL2         | -195.40     |
| Interleukin 7 receptor                                                 | IL7R        | -66.71      |
| Transforming growth factor, beta receptor III                           | TGFB3       | -50.94      |

**Soluble factors**

| Soluble factors                                                         | Gene symbol | Fold change |
|------------------------------------------------------------------------|-------------|-------------|
| Lipocalin 2                                                            | LCN2        | -217.74     |
| Adrenomedullin                                                         | ADM         | -100.37     |

**Miscellaneous**

| Miscellaneous                                                          | Gene symbol | Fold change |
|------------------------------------------------------------------------|-------------|-------------|
| Radical S-adenosyl methionine domain containing 2                      | RSAD2       | -559.34     |
| Interferon-induced transmembrane protein 3-like                        | LOC606890   | -435.57     |
| ISG15 ubiquitin-like modifier                                         | ISG15       | -254.32     |
| Apolipoprotein L, 5                                                   | APOL5       | -200.23     |
IL15RA, IL23A, INHBA, NAMPT, and SLC2A6. For canine M2-polarization, 11 genes matched reported expression in human and murine M2-macrophages, i.e. CCL24, CCL13, FCER1A, FN1, EGR2, CA2, LIPA, SLCA47, CD163, ADK, and FGL2 (Fig 5A). Conflicting results were present for the genes P2RY14, TGFBR2, and TPST2, which were expected as M2-markers based on the literature but were differentially up-regulated in canine M1-macrophages. Furthermore, PIK3CB was up-regulated by both canine M1- and M2-macrophages in the present study. The differentially expressed genes of the intersections, which are not namely mentioned in Fig 5A are listed in S4 Table. The top 50 candidate canine M1- and M2-macrophage genes, as defined above, are given in Tables 6 and 7. The full lists of canine probesets, corresponding to the 404 unique M1 genes and 700 unique M2 genes are shown in S5 Table.

Biomarker selection

In a hypothesis-driven approach, polarization specific prediction markers were detected with Prophet using the microarray data of unstimulated macrophages (M0), M1-, and M2-macrophages [41, 42]. 369 probe sets were identified by the correlation-based feature selection algorithm of Prophet that discriminated between M0-, M1-, and M2-polarity, using the KNN algorithm with 100% correct predictions. Subsequent "one versus all" analyses using SET to create ranked lists of genes, based on their potential to serve as biomarker for M1- or M2-macrophages were performed (S6 Table; [43]). The highest scoring probe set differentiating M1- from M0- and M2-macrophages was CfaAffx.14358.1.S1_at, annotated as latexin (LXN), which was up-regulated in M1-macrophages, exhibiting a prediction-accuracy for the M1-phenotype of 100%. Additionally, the probe set ID’s occupying the ranks 2 to 4 (Cfa.5195.1.A1_s_at, Cfa.5195.1.A1_at, Cfa.14007.1.A1_x_at) were similarly annotated to LXN (S6 Table). Analysis of the expression data of CfaAffx.14358.1.S1_at revealed a relatively high expression in all three polarities with a significantly higher expression in M1-macrophages as compared to M0- and M2-macrophages (pairwise Mann-Whitney-U-Tests; p = 0.02, Fig 5B). For the comparison of M2 versus M0 and M1, the highest scoring probe set was Cfa.3662.1.S1_at,
Table 5. List and subgrouping of the top hits of highly differentially expressed genes (fold change ≥ 50 or ≤ -50) in M2- vs. M1-macrophages.

| Gene name | Gene symbol | Fold change |
|-----------|-------------|-------------|
| **Cell surface markers** | | |
| Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide | FCER1A | 376.89 |
| CD209 molecule | CD209 | 335.12 |
| Lymphatic vessel endothelial hyaluronan receptor 1 | LYVE1 | 321.11 |
| C-type lectin domain family 4, member G | CLEC4G | 183.13 |
| Collectin sub-family member 12 | COLEC12 | 181.04 |
| Junctional adhesion molecule 3 | JAM3 | 145.24 |
| Membrane-spanning 4-domains, subfamily A, member 2 | MS4A2 | 137.95 |
| Stabilin 1 | STAB1 | 127.60 |
| Mannose receptor, C type 1 | MRC1 | 52.68 |
| Solute carrier family 15 (oligopeptide transporter), member 1 | SLC15A1 | 52.03 |
| **Enzymes** | | |
| Fructose-1,6-bisphosphatase 1 | FBP1 | 149.73 |
| Uronyl-2-sulfotransferase | UST | 85.20 |
| Alanyl (membrane) aminopeptidase | ANPEP | 82.13 |
| Lipoprotein lipase | LPL | 57.39 |
| **Cytokines, chemokines, and their receptors** | | |
| Chemokine (C-C motif) ligand 24 | CCL24 | 1050.11 |
| Transforming growth factor, beta 2 | TGFB2 | 66.97 |
| **Soluble factors** | | |
| CD5 molecule-like | CD5L | 209.01 |
| Secreted phosphoprotein 2, 24kDa | SPP2 | 121.14 |
| Nephronec tin | NPNT | 105.07 |
| Secretogranin V (7B2 protein) | SCG5 | 82.69 |
| Complement component 3 | C3 | 67.78 |
| Cystatin 9 (testatin) | CST9 | 58.53 |
| **Miscellaneous** | | |
| Coagulation factor XIII, A1 polypeptide | F13A1 | 1309.86 |
| Sodium channel, voltage-gated, type II, beta subunit | SCN2B | 1120.45 |
| Dynamin 1 | DNM1 | 247.10 |
| Caldesmon 1 | CALD1 | 239.74 |
| Rho GTPase activating protein 6 | ARHGAP6 | 147.58 |
| Fibronectin 1 | FN1 | 141.81 |
| Cfa-mir-125b-2 | cfa-mir-125b-2 | 103.61 |
| Plexin domain containing 2 | PLXDC2 | 71.70 |
| Transforming growth factor, beta-induced, 68kDa | TGFBI | 59.20 |
| G protein-coupled receptor 116 | GPR116 | 51.83 |

**Down-regulated genes**

| Gene name | Gene symbol | Fold change |
|-----------|-------------|-------------|
| Purinergic receptor P2Y, G-protein coupled, 14 | P2RY14 | -344.22 |
| Solute carrier family 39 (zinc transporter), member 14 | SLC39A14 | -200.01 |
| Integrin, beta 8 | ITGB8 | -134.58 |
| Transmembrane protein 150C | TMEM150C | -103.02 |
| Transmembrane protein 176A | TMEM176A | -78.17 |
| Solute carrier family 22, member 15 | SLC22A15 | -58.69 |

(Continued)
Table 5. (Continued)

| Gene name                                                                 | Gene symbol | Fold change |
|---------------------------------------------------------------------------|-------------|-------------|
| Prostaglandin E synthase                                                  | PTGES       | -1274.66    |
| Epoxide hydrolase 2, cytoplasmic                                          | EPHX2       | -222.01     |
| Interferon stimulated exonuclease gene 20kDa                             | ISG20       | -187.95     |
| Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | PTGS2       | -183.48     |
| E3 ubiquitin-protein ligase NEURL3-like                                   | LOC102152163| -156.11     |
| Indoleamine 2,3-dioxygenase 2                                             | IDO2        | -127.88     |
| STEAP family member 4                                                    | STEAP4      | -92.42      |
| Ceruloplasmin (ferroxidase)                                               | CP          | -90.30      |
| Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) | GZMB        | -69.42      |
| Phospholipase A2, group XVI-like                                          | LOC476045   | -57.39      |
| Cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial                  | CMPK2       | -57.00      |
| WNK lysine deficient protein kinase 2                                     | WNK2        | -52.30      |
| Interleukin-1 receptor-associated kinase 3                                | IRAK3       | -50.40      |

**Cytokines, chemokines, and their receptors**

| Chemokine (C-X-C motif) receptor 3                                        | CXCR3       | -140.97     |
| Chemokine (C-C motif) ligand 20                                            | CCL20       | -119.64     |
| Interleukin 6 (interferon, beta 2)                                         | IL6         | -69.50      |
| Tumor necrosis factor                                                      | TNF         | -55.63      |

**Soluble factors**

| Complement component 2                                                    | C2          | -78.67      |

**Miscellaneous**

| Peptidase inhibitor 3, skin-derived                                       | PI3         | -235.52     |
| TNFAIP3 interacting protein 3                                             | TNIP3       | -178.37     |
| Ras homolog family member U                                               | RHOU        | -168.17     |
| Radical S-adenosyl methionine domain containing 2                        | RSAD2       | -82.43      |
| Cochlin                                                                   | COCH        | -70.23      |
| Interferon, alpha-inducible protein 6                                     | IFI6        | -68.46      |
| multiple C2 domains, transmembrane 2                                     | MCTP2       | -66.09      |
| Fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) | FSCN1       | -58.64      |
| Interferon regulatory factor 4-like                                       | LOC609817   | -50.92      |
| ISG15 ubiquitin-like modifier                                             | ISG15       | -50.28      |

https://doi.org/10.1371/journal.pone.0183572.t005

annotated as *membrane-spanning 4-domains, subfamily A, member 2* (MS4A2, S6 Table). This probe set was up-regulated in M2-macrophages and displayed a prediction accuracy of 100% for this phenotype. Statistical evaluation with pairwise Mann-Whitney-U-Tests underlined a low expression of *MS4A2* in M0- and M1-macrophages, but a significantly higher expression in M2-macrophages (*p* = 0.02, Fig 5C).

**Testing of antibodies for the detection of predicted biomarkers**

In order to test, whether the biomarkers predicted to distinguish between canine M0-, M1-, and M2-macrophages during the transcriptome investigations are also mirrored by altered protein expression, an additional experiment using blood from 3 dogs was performed. The cells were isolated and polarized as described and labeled with antibodies targeting MS4A2 and LXN (Table 1). There was protein expression in canine macrophages in vitro for both molecules (Fig 6). However, the percentage of cells labeled with an antibody against MS4A2 showed no differences between M0-, M1-, and M2-macrophages (*p* = 0.117; Fig 6). The
of positive cells for LXN was significantly higher in both M1- and M2-macrophages as compared to M0-macrophages ($p = 0.02$ and $p = 0.01$, respectively); however, there was no difference in the percentage of LXN-immunopositive cells between M1- and M2-macrophages ($p = 0.06$; Fig 6).
Fig 5. Comparative evaluation of canine M1- and M2-associated differentially expressed genes (M1 = 404; M2 = 700) with established literature-based human and murine orthologous genes (A) and detection of polarization-specific biomarkers employing supervised clustering with a K-nearest-neighbors algorithm and correlation-based feature selection using Prophet (B, C). A) The Venn diagram depicts the numbers and intersections of differential and common canine M1- and M2-genes with literature-based human and murine genes. The majority of literature-based M1- (65 genes = 57+8) and M2-markers (58 genes = 44+11+3) did not comply with the present microarray data upon canine macrophages. However, overlapping expression of 8 genes for the M1-phenotype and 11 genes for the M2-phenotype was identified. The genes of the intersections, not specifically mentioned in the figure, are listed in S4 Table. B) Biomarker selection detected 4 highly specific probe sets for annotated by the mammalian carboxypeptidase inhibitor latexin (LXN) to be highly correlated to the M1-phenotype. The boxplots depict the significantly enhanced log₂-transformed expression values for LXN in M1-macrophages as compared to both M0- and M2-macrophages (p = 0.002), as well as between M0- and M2-macrophages (p = 0.002). C) For the M2-phenotype, the most significant predicted biomarker was high affinity receptor for IgE, i.e. membrane-spanning 4-domains, subfamily A, member 2 (MS4A2). The expression data of M2-macrophages show significantly higher log₂-transformed expression values as compared to both M0- and M1-macrophages (p = 0.002) as well as between M0- and M1-macrophages (p = 0.002). Asterisks indicate significance (Kruskal-Wallis-Test with subsequent pairwise Mann-Whitney-U-Tests).
Table 6. Top 50 candidate M1-macrophage associated probesets, which were upregulated in M1- vs. M0-macrophages and simultaneously down-regulated in M2- vs. M1-macrophages.

| Probe Set ID      | Gene Symbol | Fold change M1 vs. M0 | Fold change M2 vs. M1 |
|-------------------|-------------|-----------------------|-----------------------|
| Cfa.12190.1.A1_at | PTGES       | 3.34                  | -1274.66              |
| CfaAffx.30585.1.S1_s_at | PTGES       | 4.99                  | -1136.51              |
| CfaAffx.30585.1.S1_at | PTGES       | 4.84                  | -517.22               |
| CfaAffx.927.1.S1_at | P2RY14      | 4.80                  | -344.22               |
| Cfa.20456.1.S1_at | IFI6        | 269.13                | -284.48               |
| CfaAffx.15155.1.S1_s_at | PTGES       | 27.22                | -235.52               |
| Cfa.574.1.A1_at   | EPHX2       | 119.72                | -222.01               |
| Cfa.18083.1.S1_s_at | SLC39A14    | 15.89                | -212.19               |
| CfaAffx.14855.1.S1_s_at | SLC39A14   | 13.48                | -200.01               |
| Cfa.3449.1.S1_s_at | PTGS2       | 27.78                | -183.48               |
| Cfa.15554.1.A1_at | TNIp3       | 3.07                  | -178.37               |
| Cfa.9253.1.A1_at  | RHOU        | 446.23                | -168.17               |
| Cfa.12477.1.A1_at | LOC102152163 | 86.20                | -156.11               |
| Cfa.15339.1.A1_at | CXCR3       | 5.70                  | -140.97               |
| Cfa.10779.1.A1_at | IDO2        | 28.65                | -127.88               |
| CfaAffx.13394.1.S1_s_at | EPHX2       | 110.24                | -122.12               |
| Cfa.15812.1.S1_at | CCL20       | 67.90                | -119.64               |
| Cfa.1856.1.S1_at  | TMEM150C    | 40.36                | -103.02               |
| Cfa.2878.1.S1_s_at | CP          | 425.52                | -96.02                |
| CfaAffx.3697.1.S1_at | STEAP4     | 11.45                | -92.42                |
| CfaAffx.13209.1.S1_s_at | CP      | 161.88                | -90.30                |
| Cfa.8846.1.A1_s_at | C2 /// CFB  | 4.39                  | -78.67                |
| CfaAffx.7919.1.S1_at | TMEM176A   | 19.58                | -78.17                |
| CfaAffx.1718.1.S1_at | TNF       | 47.17                | -71.34                |
| Cfa.3528.1.S1_s_at | IL6        | 252.32                | -69.50                |
| Cfa.20456.1.S1_s_at | IFI6       | 68.64                 | -68.46                |
| CfaAffx.17110.1.S1_s_at | MCTP2     | 2.69                  | -66.09                |
| CfaAffx.15348.1.S1_at | SLC22A15   | 15.67                | -58.69                |
| CfaAffx.24565.1.S1_s_at | FSCN1     | 35.83                | -58.64                |
| Cfa.12164.1.A1_at | LOC476045   | 5.65                  | -57.39                |
| Cfa.54.1.S1_s_at  | TNF        | 47.20                | -55.63                |
| Cfa.11870.1.A1_at | PI3        | 17.25                 | 52.33                 |
| Cfa.4359.1.S1_at  | WNK2       | 52.35                 | 52.30                 |
| CfaAffx.1510.1.S1_s_at | IRAK3    | 10.70                | 50.40                 |
| CfaAffx.15202.1.S1_s_at | SDC4      | 58.61                | 49.56                 |
| CfaAffx.1352.1.S1_s_at | IL22RA2   | 116.00                | 48.48                 |
| CfaAffx.26233.1.S1_s_at | CXCR3   | 32.55                | 47.23                 |
| CfaAffx.17136.1.S1_s_at | MCTP2   | 6.25                 | 46.94                 |
| CfaAffx.24086.1.S1_at | KMO       | 23.66                 | 46.48                 |
| CfaAffx.15086.1.S1_s_at | BMP1     | 43.14                | 43.31                 |
| CfaAffx.9261.1.S1_at | HCAR3     | 13.88                | 42.20                 |
| Cfa.18962.1.S1_s_at | SGK1       | 20.11                | 39.12                 |
| Cfa.3719.1.S1_s_at  | QPCT       | 22.78                | 38.99                 |
| Cfa.4926.1.A1_s_at  | LOC476045  | 5.41                 | 37.14                 |
| CfaAffx.6260.1.S1_at | C18H7orf10 | 43.19                | 36.13                 |
| Cfa.6458.1.A1_s_at  | C2 /// CFB | 5.05                | -36.01                |
Discussion

The current investigation is the first report upon the properties of canine polarized macrophages in vitro with a special emphasis on the establishment of unique distinctive gene signatures. Even though in vitro data on macrophage polarization doubtlessly cannot be simply extrapolated to in vivo situations and the paradigm of M1-/M2-polarization represents a simplified approach, which depicts only two extremes of macrophage heterogeneity [8, 48–50], this initial reductionistic in vitro approach will provide a basis for future investigations on the role of macrophage polarization in both healthy and diseased dogs.

Striking morphological differences were observed between canine M0-, M1-, and M2-macrophages, which are most probably attributed to direct effects of cytokine stimulation. Similar to observations in other species [51–54], M1-macrophage cultures appeared to dominantly adapt an amoeboid morphology, although a significant proportion of M0-macrophages also obtained such an amoeboid morphology. Notably, M2-cultures were rather heterogeneous including spindeloid cells and MNGs, which is in line with previous observations in human and murine bone marrow- and blood-derived M2-macrophages [51–54]. Interestingly, stimulation of macrophages with IL-4 and IL-13 together with colony stimulation factors can lead to the formation of MNGs [55–58]. The recent observation of MNG formation, exclusively in canine M2-cultures, is consistent with reports from other species [44, 57, 59].

A variety of different phenotypic markers has been proposed for the differentiation of human and murine M1- and M2-macrophages [4, 31]. Even though a multitude of antibodies targeting immune cells including macrophages is known to cross-react with canine antigens [60–63], commercially available antibodies explicitly designed for the use on canine cells and tissues are frequently not available. The prototypical literature-based M1-markers CD16, CD32, and iNOS and the M2-markers CD163 and arginase-1 were demonstrated to be inappropriate for the immunophenotypic discrimination of M0-, M1-, and M2-polarization states in canine macrophages in the present study. This may in part be explained by interspecies differences [64, 65]. For instance, following classical stimulation with pro-inflammatory cytokines, murine macrophages produce NO, whereas human macrophages nearly lack synthesis of NO in response to classically activating stimuli [66, 67]. Moreover, arginase-1 has been reported as a prototype marker for murine M2-macrophages, which is however inappropriate for the detection of human M2-macrophages [13, 44, 68, 69]. Based on the present observations, canine macrophages may thus share closer similarities with human than murine macrophages, thus underlining the role of dogs in translational research. Similar to the immunofluorescence data, and supporting the results of the immunophenotyping, expression values for all probesets annotated with the canine genes NOS2 (2 probesets) and ARG1 (3 probesets), which encode iNOS and arginase-1, respectively, also lacked differences in their expression values between M0-, M1- and M2-macrophages (data available under accession number: E-MTAB-5458; http://www.ebi.ac.uk/arrayexpress). MHC class II is sometimes regarded as a marker for classically activated M1 macrophages [70]; however, a substantial fundus of literature also indicates MHC class II as a pan-macrophage marker, which is expressed on both M1 and M2 macrophages in mice and

Table 6. (Continued)

| Probe Set ID       | Gene Symbol | Fold change M1 vs. M0 | Fold change M2 vs. M1 |
|--------------------|-------------|-----------------------|-----------------------|
| Cfa.8282.1.A1_s_at | KBTBD7      | 3.64                  | -35.38                |
| CfaAffx.8143.1.S1_at| KBTBD7      | 2.59                  | -35.14                |
| Cfa.21252.1.S1_s_at| ENPP2       | 188.74                | -34.85                |
| CfaAffx.16422.1.S1_s_at| CCL20   | 33.43                | -34.83                |

https://doi.org/10.1371/journal.pone.0183572.t006
Table 7. Top 50 candidate M2-macrophage associated probesets, which were upregulated in M2- vs. M0-macrophages and simultaneously upregulated in M2- vs. M1-macrophages.

| Probe Set ID | Gene Symbol | Fold change M2 vs. M0 | Fold change M2 vs. M1 |
|--------------|-------------|-----------------------|-----------------------|
| Cfa.11125.1.A1_at | SCN2B | 1061.28 | 1120.45 |
| Cfa.15823.1.S1_at | CCL24 | 1060.82 | 1050.11 |
| CfaAffx.18273.1.S1_at | FCER1A | 35.63 | 922.72 |
| CfaAffx.20721.1.S1_s_at | CCL24 | 819.06 | 819.06 |
| Cfa.17541.1.S1_at | FBP1 | 160.02 | 748.69 |
| CfaAffx.2850.1.S1_s_at | FBP1 | 57.95 | 422.21 |
| Cfa.3663.1.A1_s_at | FCER1A | 21.07 | 376.89 |
| Cfa.3707.1.A1_at | FN1 | 12.68 | 360.42 |
| CfaAffx.12229.1.S1_at | LYVE1 | 322.32 | 321.11 |
| Cfa.10966.1.A1_at | DNM1 | 112.78 | 247.10 |
| Cfa.6272.1.S1_at | CALD1 | 224.66 | 239.74 |
| CfaAffx.1504.1.S1_s_at | UST | 7.71 | 226.47 |
| Cfa.2693.1.A1_at | LOC102152647 | 194.28 | 194.28 |
| Cfa.3707.1.S1_s_at | FN1 | 7.26 | 188.32 |
| CfaAffx.28024.1.S1_at | CLEC4G | 54.14 | 183.13 |
| CfaAffx.16206.1.S1_s_at | MS4A2 | 110.05 | 167.77 |
| Cfa.6369.1.A1_at | FBP1 | 26.98 | 149.73 |
| Cfa.20346.1.S1_at | ARHGAP6 | 37.99 | 147.58 |
| Cfa.1705.1.A1_at | JAM3 | 78.46 | 145.24 |
| Cfa.3662.1.S1_at | MS4A2 | 54.98 | 137.95 |
| Cfa.19567.1.S1_at | UST | 8.05 | 120.81 |
| CfaAffx.16206.1.S1_s_at | MS4A2 | 76.56 | 108.61 |
| Cfa.3774.1.A1_s_at | ANPEP | 25.55 | 105.73 |
| Cfa.14465.1.S1_at | NPNT | 444.07 | 105.07 |
| Cfa.688.1.S1_at | cfa-mir-125b-2 | 58.78 | 103.61 |
| CfaAffx.7700.1.S1_s_at | MRC1 | 136.99 | 89.14 |
| Cfa.2468.1.A1_at | UST | 6.54 | 85.20 |
| Cfa.10794.1.A1_at | SCG5 | 6.75 | 82.69 |
| Cfa.20798.1.S1_s_at | ANPEP | 14.09 | 82.13 |
| CfaAffx.14701.1.S1_s_at | STAB1 | 4.00 | 81.41 |
| CfaAffx.28463.1.S1_at | C3 | 36.53 | 76.45 |
| Cfa.12240.1.A1_at | C3 | 44.14 | 67.78 |
| CfaAffx.16904.1.S1_s_at | TGFBI | 61.84 | 66.97 |
| CfaAffx.7365.1.S1_at | CST9 | 58.21 | 58.53 |
| CfaAffx.15901.1.S1_s_at | LPL | 52.03 | 57.39 |
| CfaAffx.7698.1.S1_at | MRC1 | 104.41 | 52.68 |
| Cfa.78.1.S1_s_at | SLC15A1 | 14.65 | 52.03 |
| CfaAffx.27914.1.S1_s_at | IL13RA2 | 170.59 | 46.70 |
| Cfa.19638.1.S1_s_at | TMLHE | 51.05 | 45.55 |
| CfaAffx.22229.1.S1_at | GPR34 | 6.30 | 42.39 |
| CfaAffx.21392.1.S1_s_at | FKBPL | 25.81 | 40.60 |
| CfaAffx.19151.1.S1_s_at | ADCY4 | 14.07 | 39.02 |
| Cfa.11222.1.A1_s_at | FAM185A | 23.07 | 38.03 |
| Cfa.10053.1.A1_at | RAB40B | 48.86 | 37.88 |
| CfaAffx.24797.1.S1_at | EPXH1 | 3.75 | 36.82 |
| Cfa.1930.1.S1_at | MRC1 | 25.70 | 36.76 |

(Continued)
humans without discriminating between both phenotypes [4, 7, 68]. Concordantly, the immunofluorescence data demonstrated that MHC class II was found to distinguish between canine M2- and M0-macrophages with a lower expression in the latter (Fig 3). In fact, it is well known that IL-4 acts as a potent activator of macrophages and induces an up-regulation of MHC class II [23, 71–75]. However, it must be critically considered that MHC class II appeared inappropriate for the differentiation of canine M0- and M1-macrophages on the protein level, which contradicts reported up-regulation of MHC class II on M1 macrophages [7]. Whether these differences are attributed to true species effects or whether the low number of investigated animals and the quantification method (immunofluorescence) are responsible for not reaching the level of significance remains to be determined.

Conclusively, it is unlikely that a single antibody will be sufficient to specifically detect canine M1- and M2-macrophages in vivo. Due to the paucity of commercially available antibodies detecting canine antigens this will probably also involve the generation of antibodies targeting canine epitopes.

The present study thus aimed to set up a transcriptomic basis that should encourage future attempts to establish a broader antibody panel against antigens, which are predicted to potentially represent discriminating markers for canine macrophage phenotypes. Interestingly, in the present study, CD206 was among the top regulated genes of canine M2 macrophages on the transcriptome level, and the results of the immunophenotyping also validated CD206 as a promising marker for canine M2 polarized macrophages. This implies that CD206 might constitute a conserved marker, which is appropriate for labeling M2-macrophages in various species including the dog [4, 27, 31, 72, 76]. However, a limitation of the present study is that the suitability of markers identified in the transcriptome analyses either still needs to be verified on the protein level or produced partially conflicting results in the immunofluorescence investigations (i.e. CD163, LXN, and MS4A2).

For M1-associated up-regulated genes, multiple metabolic pathways such as "steroid biosynthesis", and "glycolysis/glucogenesis" demonstrated to be enriched in the functional annotation of microarray data. Human and murine monocyte to macrophage differentiation has previously been shown to go along with profound changes in the lipid metabolism as a prerequisite for phagocytosis [77]. Moreover, in the hierarchical clustering analysis, the M1-specific cluster was functionally annotated to biological processes involved in "respiratory burst". M1 macrophages produce a variety of pro-inflammatory mediators including ROS, whereas in contrast, IL-4 inhibits the respiratory burst [78].

Enriched terms related to the peroxisome proliferator activated receptor (PPAR) signaling pathway were retrieved for the comparison of M2 vs. M1 up-regulated genes. PPARγ is a member of the nuclear receptor superfamily with potent anti-inflammatory properties and regulatory functions in fatty acid metabolism [79–82]. Interestingly, PPARγ agonists such as rosiglitazone induce an alternative M2a-activation state in murine macrophages and have been used as neuroprotective agents [83, 84]. Pharmacological approaches, designed to enhance M2-dominated immune responses may thus similarly represent a promising tool in canine diseases.

| Probe Set ID     | Gene Symbol | Fold change M2 vs. M0 | Fold change M2 vs. M1 |
|------------------|-------------|-----------------------|-----------------------|
| Cfa.3367.1.A1_at | TGFB2       | 36.49                 | 36.58                 |
| Cfa.15824.1.S1_at| CCL13       | 172.58                | 34.71                 |
| Cfa.14297.1.A1_s_at | MAOB     | 33.75                 | 33.75                 |
| Cfa.12621.1.A1_at | LRP4       | 7.01                  | 33.01                 |

Table 7. (Continued)
Interestingly, multiple biological processes related to an enhanced cell cycle were enriched in canine M2-macrophages as compared to both M0- and M1-macrophages. IL-4 has previously been reported to induce local macrophage proliferation in the context of chronic inflammation [59]. Moreover, human monocyte to macrophage differentiation in the presence of M-CSF is associated with a dramatic regulation of multiple cell-cycle genes [44]. The
transcriptomic link to enhanced cell cycle and proliferation is probably also reflected by the higher cell number of M2-macrophages in the present study as compared to M0-macrophages (S1 Fig).

Comparison of the canine transcriptome data with published murine and human prototype markers demonstrated a relatively low overlap. This confirms recent reports on marked interspecies differences between polarized macrophages [13] and suggests that some properties of polarized macrophages are unique to the dog, demonstrating that reported literature-based markers cannot simply be transferred to another species.

Based on this observation we sought to predict novel transcriptomic markers using a hypothesis-driven approach. Using a correlation-based algorithm, the carboxypeptidase inhibitor latexin (LXN) [85–88] was retrieved for canine M1-macrophages. Though LXN-expression by murine macrophages upon pro-inflammatory stimulation has been demonstrated [85], LXN has so far not been proposed as a marker for M1-macrophages in the literature for any species. For the canine M2-phenotype, the high-affinity receptor for IgE membrane-spanning 4-domains, subfamily A, member 2 (MS4A2) was predicted to represent the most powerful biomarker. Interestingly, other members of the molecule family, i.e. MS4A4A and MS4A6A, have been previously shown to be associated with M2-polarization [4, 44, 89]. In an attempt to validate LXN and MS4A2 as markers for canine macrophages, we demonstrated that MS4A2 showed no differences in the percentage of immunopositive cells between the three conditions. The percentage of immunopositive cells for LXN was higher in both M1- and M2-macrophages as compared to M0-macrophages. However, similar to MS4A2, LXN failed to distinguish between canine M1- and M2-macrophages. Thus, similar to CD163, the protein data did not accurately mirror the transcriptomic prediction. This could be attributed to conflicting differences between RNA- and protein level for these molecules. However, the low number of dogs tested and the fact that low level differences in protein expression may not be detected by immunofluorescence have certainly influenced the statistical power and sensitivity, and thus future validating experiments both in canine tissues and in vitro remain to be performed.

Supporting information

S1 Fig. Dot plot diagrams depicting differences in the absolute number of cells per field (200x) in canine M0-, M1-, and M2-macrophages derived from 3 dogs on day 7 in culture. One-factorial ANOVA with group-wise t tests reveals a significantly higher number of cells in M2-polarized macrophages as compared to non-stimulated (M0)-macrophages (p<0.05; asterisk).

S1 Table. List of the genes included in the M1-associated cluster of the hierarchical clustering analysis (refer to Fig 3).

S2 Table. List of the genes included in the M2-associated cluster of the hierarchical clustering analysis (refer to Fig 3).

S3 Table. Overview on retrieved enriched gene ontology biological processes and KEGG pathways of the clusters, resulting from the hierarchical clustering analysis (refer to Fig 3).

S4 Table. List for the intersections of differentially expressed genes in the comparison of literature-based human and murine markers with canine M1- and M2-associated genes as
retrieved by the present study (refer to Fig 4). Excel table.

(S5 Table. Lists of differentially expressed M1- and M2-macrophage associated probesets with fold change. Sheet 1 depicts all genes, which were upregulated in M1- vs. M0-macrophages and simultaneously downregulated in M2- vs M1-macrophages (i.e. canine M1-macrophage genes). Sheet 2 shows all genes, which were upregulated in M2- vs. M0-macrophages and simultaneously upregulated in M2- vs M1-macrophages (i.e. canine M2-macrophage genes). Excel table)

(S6 Table. Selected biomarkers predicted to discriminate between canine M1- and M2- macrophages as retrieved and ranked by Prophet. DOCX)

Acknowledgments
This study was in part supported by the German Research Foundation (FOR 1103; BA 815/10-2 and UL 421/1-2) and in part by the Niedersachsen-Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Franziska Heinrich was supported by the German National Academic Foundation, Bonn, Germany. AK and UD are employed by the commercial company Boehringer Ingelheim Pharma GmbH & Co. KG. The funder provided support in the form of salaries for authors [AK, UD], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section. This does not alter our adherence to PLOS ONE policies on sharing data and materials. We acknowledge the contribution of the Institute for Parasitology of the University of Veterinary Medicine Hannover for providing blood samples from dogs. The authors gratefully thank Anuschka Unold, Kerstin Rohn, Regina Carlson, Danuta Waschke, Kerstin Schöne, and Caroline Schütz for excellent technical support.

Author Contributions
Conceptualization: Franziska Heinrich, Wolfgang Baumgärtner, Reiner Ulrich, Ingo Spitzbarth.

Data curation: Franziska Heinrich, Reiner Ulrich, Ingo Spitzbarth.

Formal analysis: Franziska Heinrich, Annika Lehmbecker, Reiner Ulrich, Ingo Spitzbarth.

Funding acquisition: Wolfgang Baumgärtner, Reiner Ulrich.

Investigation: Franziska Heinrich, Annika Lehmbecker, Barbara B. Raddatz, Reiner Ulrich, Ingo Spitzbarth.

Methodology: Reiner Ulrich.

Project administration: Wolfgang Baumgärtner, Reiner Ulrich, Ingo Spitzbarth.

Resources: Andrea Tipold, Veronika M. Stein, Arno Kalkuhl, Ulrich Deschl.

Software: Arno Kalkuhl, Ulrich Deschl.

Supervision: Wolfgang Baumgärtner, Reiner Ulrich, Ingo Spitzbarth.
References

1. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008; 8: 958–969. https://doi.org/10.1038/nri2448 PMID: 19029990

2. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012; 122: 787–795. https://doi.org/10.1172/JCI59643 PMID: 22378047

3. Stout RD, Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol. 2004; 76: 509–513. https://doi.org/10.1189/jlb.0504272 PMID: 15218057

4. David S, Kroner A. Repertoire of microglial and macrophage responses after spinal cord injury. Nat Rev Neurosci. 2011; 12: 388–399. https://doi.org/10.1038/nrn3053 PMID: 21673720

5. Hume DA, Freeman TC. Transcriptional analysis of mononuclear phagocyte differentiation and activation. Immunol Rev. 2014; 262: 74–84. https://doi.org/10.1111/imr.12211 PMID: 25319328

6. Gerhauser I, Hansmann F, Puff C, Kumnok J, Schaudien D, Wewetzer K, et al. Theiler’s murine encephalomyelitis virus induced phenotype switch of microglia in vitro. J Neuroimmunol. 2012; 252: 49–55. https://doi.org/10.1016/j.jneuroim.2012.07.018 PMID: 22967352

7. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014; 6: 13. https://doi.org/10.12703/P6-13 PMID: 24669294

8. Herder V, Iskandar CD, Kegler K, Hansmann F, Elmaret J, Mahmoud A, et al. Dynamic Changes of Microglia/Macrophage M1 and M2 Polarization in Theiler’s Murine Encephalomyelitis. Brain Pathol. 2015; 25: 712–723. https://doi.org/10.1111/bpa.12238 PMID: 25495532

9. Liu YC, Zou XB, Chai YF, Yao YM. Macrophage polarization in inflammatory diseases. Int J Biol Sci. 2014; 10: 520–529. https://doi.org/10.7150/ijbs.8879 PMID: 24910531

10. Orhuela R, McPherson CA, Harris J, McPherson CA, Harris J, McPherson CA, Harris J, McPherson CA, Harris J. Microglial M1/M2 polarization and metabolic states. Br J Pharmacol. 2016; 173: 649–665. https://doi.org/10.1111/bph.13139 PMID: 25800044

11. Beyer M, Mallmann MR, Xue J, Staratschek-Jox A, Vorholt D, Krebs W, et al. High-resolution transcriptome of human macrophages. PLoS One. 2012; 7: e0119751. https://doi.org/10.1371/journal.pone.0119751 PMID: 23029029

12. Derlindati E, Dei Cas A, Montanini B, Spigoni V, Curella V, Aldigeri R, et al. Transcriptomic analysis of human polarized macrophages: more than one role of alternative activation? PLoS One. 2015; 10: e0119751. https://doi.org/10.1371/journal.pone.0119751 PMID: 25797240

13. Martinez FO, Helming L, Milde R, Varin A, Melgert BN, Draijer C, et al. Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. Blood. 2013; 121: e57–69. https://doi.org/10.1182/blood-2012-06-436212 PMID: 23293084

14. Xue J, Schmidt SV, Sander J, Draifneh A, Krebs W, Quester I, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014; 40: 274–288. https://doi.org/10.1016/j.immuni.2014.01.006 PMID: 24530056

15. Bock P, Spitzbarth I, Haist V, Stein VM, Tipold A, Puff C, et al. Spatio-temporal development of axonopathy in canine intervertebral disc disease as a translational large animal model for nonexperimental spinal cord injury. Brain Pathol. 2013; 23: 82–99. https://doi.org/10.1111/j.1750-3639.2012.00617.x PMID: 22865224

16. Boekhoff TM, Ensinger EM, Carlson R, Bock P, Baumgaertner W, Rohn K, et al. Microglial contribution to secondary injury evaluated in a large animal model of human spinal cord trauma. J Neurotrauma. 2012; 29: 1000–1011. https://doi.org/10.1089/neu.2011.1821 PMID: 21599492

17. Lapp S, Flankuche VM, Baumgärtner W, Puff C. Viral oncology—can insights from measles be transferred to canine distemper virus? Viruses. 2014; 6: 2340–2375. https://doi.org/10.3390/v6062340 PMID: 24921409

18. Rowell JL, McCarthy DO, Alvarez CE. Dog models of naturally occurring cancer. Trends Mol Med. 2011; 17: 380–388. https://doi.org/10.1016/j.molmed.2011.02.004 PMID: 21439907
19. Seehusen F, Baumgärtner W. Axonal pathology and loss precede demyelination and accompany chronic lesions in a spontaneously occurring animal model of multiple sclerosis. Brain Pathol. 2010; 20: 551–559. https://doi.org/10.1111/j.1750-3639.2009.00332.x PMID: 19775292

20. Spitzbarth I, Bock P, Haist V, Stein VM, Tipold A, Wewetzer K, et al. Prominent microglial activation in the early proinflammatory immune response in naturally occurring canine spinal cord injury. J Neuropathol Exp Neurol. 2011; 70: 703–714. https://doi.org/10.1097/NEN.0b013e3182270f8e PMID: 21760535

21. Lempp C, Spitzbarth I, Puff C, Cana A, Kegler K, Techangamsuwan S, et al. New aspects of the pathogenesis of canine distemper leukoencephalitis. Viruses. 2014; 6: 2571–2601. https://doi.org/10.3390/v6072571 PMID: 24992230

22. Stein VM, Czub M, Hansen R, Leibold W, Moore PF, Zurbriggen A, et al. Characterization of canine microglial cells isolated ex vivo. Vet Immunol Immunopathol. 2004; 99: 73–85. https://doi.org/10.1016/j.vetimm.2004.01.002 PMID: 15113656

23. de Waal Malefyt R, Figdor CG, Huijbens R, Mohan-Petersen S, Bennett B, Culpepper J, et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol. 1993; 151: 6370–6381. PMID: 7902377

24. Delirezh N, Shojaeefar E, Parvin P, Asadi B. Comparison the effects of two monocyte isolation methods, plastic adherence and magnetic activated cell sorting methods, on phagocytic activity of generated dendritic cells. Cell J. 2013; 15: 218–223. PMID: 24027662

25. Frackowiak J, Mazur-Kolecka B, Carroll RT, Chauhan A, Wisniewski HM. Factors secreted by activated microglia and monocytes reduce amyloidogenesis in vascular smooth muscle cells. Neuroreport. 1997; 8: 2259–2263. PMID: 9243622

26. Gamble JR, Elliott MJ, Jaipargas E, Lopez AF, Vadas MA. Regulation of human monocyte adherence by granulocyte-macrophage colony-stimulating factor. Proc Natl Acad Sci U S A. 1989; 86: 7169–7173. PMID: 2674950

27. Durafout BA, Moore CS, Zammit DA, Johnson TA, Zaguia F, Guiot MC, et al. Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia. 2012; 60: 719–727.

28. Pringproa K, Rohn K, Kummerfeld M, Wewetzer K, Baumgärtner W. Theiler’s murine encephalomyelitis virus preferentially infects immature stages of the murine oligodendrocyte precursor cell line BO-1 and blocks oligodendrocytic differentiation in vitro. Brain Res. 2010; 1327: 24–37. https://doi.org/10.1016/j.brainres.2010.02.068 PMID: 20206147

29. Kegler K, Imbschweiler I, Ulrich R, Koversmann P, Fahlike C, Deschl U, et al. CNS Schwann cells display oligodendrocyte precursor-like potassium channel activation and antigenic expression in vitro. J Neural Transm (Vienna). 2014; 121: 569–581.

30. Ziege S, Baumgärtner W, Wewetzer K. Toward defining the regenerative potential of olfactory mucosa: establishment of Schwann cell-free adult canine olfactory ensheathing cell preparations suitable for transplantation. Cell Transplant. 2013; 22: 355–367. https://doi.org/10.3727/096368912X656108 PMID: 23006619

31. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci. 2009; 29: 13435–13444. https://doi.org/10.1523/JNEUROSCI.3257-09.2009 PMID: 19864556

32. Ulrich R, Puff C, Wewetzer K, Kalkuhl A, Deschl U, Baumgärtner W. Transcriptional changes in canine distemper virus-induced demyelinating leukoencephalitis favor a biphasic mode of demyelination. PLoS One. 2014; 9: e95917. https://doi.org/10.1371/journal.pone.0095917 PMID: 24755553

33. Medina I, Carbonell J, Pulido L, Madeira SC, Goetz S, Conesa A, et al. Babelomics: an integrative platform for the analysis of transcriptomics, proteomics and genomic data with advanced functional profiling. Nucleic Acids Res. 2010; 38: W210–213. https://doi.org/10.1093/nar/gkq388 PMID: 20478823

34. Raddatz BB, Hansmann F, Spitzbarth I, Kalkuhl A, Deschl U, Baumgärtner W, et al. Transcriptomic meta-analysis of multiple sclerosis and its experimental models. PLoS One. 2014; 9: e86643. https://doi.org/10.1371/journal.pone.0086643 PMID: 24475162

35. Ulrich R, Kalkuhl A, Deschl U, Baumgärtner W. Machine learning approach identifies new pathways associated with demyelination in a viral model of multiple sclerosis. J Cell Mol Med. 2010; 14: 434–448. https://doi.org/10.1111/j.1582-4934.2008.00664.x PMID: 19183246

36. Pfankuche VM, Spitzbarth I, Lapp S, Ulrich R, Deschl U, Kalkuhl A, et al. Reduced angiogenic gene expression in morbillivirus-triggered oncolysis in a translational model for histiocytic sarcoma. J Cell Mol Med. 2016.
37. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012; 40: D109–114. https://doi.org/10.1093/nar/gkr988 PMID: 22080510

38. Wang J, Duncan D, Shi Z, Zhang B. WEB-based GEnE SeT AnaLYsis Toolkit (WebGestalt): update 2013. Nucleic Acids Res. 2013; 41: W77–83. https://doi.org/10.1093/nar/gkt439 PMID: 23703215

39. Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 2005; 33: W741–748. https://doi.org/10.1093/nar/gki475 PMID: 15980575

40. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003; 34: 374–378. PMID: 12613259

41. Medina I, Montaner D, Tarraga J, Dopazo J. Prophet, a web-based tool for class prediction using microarray data. Bioinformatics. 2007; 23: 390–391. https://doi.org/10.1093/bioinformatics/btl602 PMID: 17138587

42. Ulrich R, Imbschweiler I, Kaikhah A, Lehmbcker A, Ziege S, Kegler K, et al. Transcriptional profiling predicts overwhelming homology of Schwann cells, olfactory ensheathing cells, and Schwann cell-like glia. Glia. 2014; 62: 1559–1581. https://doi.org/10.1002/glia.22700 PMID: 24889922

43. Jen CH, Yang TP, Tung CY, Su SH, Lin CH, Hsu MT, et al. Signature Evaluation Tool (SET): a Java-based tool to evaluate and visualize the sample discrimination abilities of gene expression signatures. BMC Bioinformatics. 2008; 9: 58. https://doi.org/10.1186/1471-2105-9-58 PMID: 18221568

44. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006; 177: 7303–7311. PMID: 17082649

45. Prajeeth CK, Lohr K, Floess S, Zimmermann J, Ulrich R, Gudi V, et al. Effector molecules released by Th1 but not Th17 cells drive an M1 response in microglia. Brain Behav Immun. 2014; 37: 248–259. https://doi.org/10.1016/j.bbi.2014.01.001 PMID: 24412213

46. Hoffmann R, Valenca A. A gene network for navigating the literature. Nat Genet. 2004; 36: 664. https://doi.org/10.1038/ng0704-664 PMID: 15226743

47. Mantovani A, Locati M. Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. Arterioscler Thromb Vasc Biol. 2013; 33: 1478–1483. https://doi.org/10.1161/ATVBAHA.113.300168 PMID: 23766387

48. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25: 677–686. https://doi.org/10.1016/j.it.2004.09.015 PMID: 15530839

49. Miron VE, Franklin RJ. Macrophages and CNS remyelination. J Neurochem. 2014; 130: 165–171. https://doi.org/10.1111/jnc.12705 PMID: 24601941

50. McWhorter FY, Wang T, Nguyen P, Chung T, Liu WF. Modulation of macrophage phenotype by cell shape. Proc Natl Acad Sci U S A. 2013; 110: 17253–17258. https://doi.org/10.1073/pnas.1308887110 PMID: 24101477

51. Verekyen EJ, Heijnen PD, Baron W, de Vries EH, Dijkstra CD, Teunissen CE. Classically and alternatively activated bone marrow derived macrophages differ in cytoskeletal functions and migration towards specific CNS cell types. J Neuroinflammation. 2011; 8: 58. https://doi.org/10.1186/1742-2094-8-58 PMID: 21615896

52. Verreck FA, de Boer T, Langenberg DM, van der Zanden L, Ottenhoff TH. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. J Leukoc Biol. 2006; 79: 285–293. https://doi.org/10.1189/jlb.0105013 PMID: 16330536

53. Waldo SW, Li Y, Buono C, Zhao B, Billings EM, Chang J, et al. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol. 2008; 172: 1112–1126. https://doi.org/10.2353/ajpath.2008.070501 PMID: 18321997

54. Hornik TC, Neniskyte U, Brown GC. Inflammation induces multinucleation of Microglia via PKC inhibition of cytokinesis, generating highly phagocytic multinucleated giant cells. J Neurochem. 2014; 128: 650–661. https://doi.org/10.1111/jnc.12477 PMID: 24117490

55. Jay SM, Skokos E, Laiwalla F, Krady MM, Kyriakides TR. Foreign body giant cell formation is preceded by lamellipodia formation and can be attenuated by inhibition of Rac1 activation. Am J Pathol. 2007; 171: 632–640. https://doi.org/10.2353/ajpath.2007.061213 PMID: 17556592
Characterization of polarized canine macrophages

57. Moreno JL, Mikhailenko I, Tondravi MM, Keegan AD. IL-4 promotes the formation of multinucleated giant cells from macrophage precursors by a STAT6-dependent, homotypic mechanism: contribution of E-cadherin. J Leukoc Biol. 2007; 82: 1542–1553. https://doi.org/10.1189/jlb.0107058 PMID: 17855502

58. Suzumura A, Tamura T, Yoshikawa M, Takayanagi T. Multinucleated giant cell formation by microglia: induction by interleukin (IL)-4 and IL-13. Brain Res. 1999; 849: 239–243. PMID: 10592309

59. Jenkins SJ, Ruckert D, Thomas GD, Hamilton JP, Burnham B, et al. IL-4 directly signals tissue-resident macrophages to proliferate beyond homeostatic levels controlled by CSF-1. J Exp Med. 2013; 210: 2477–2491. https://doi.org/10.1084/jem.20121999 PMID: 24101381

60. Wunschmamm A, Kremmer E, Baumgärtner W. Phenotypical characterization of T and B cell areas in lymphoid tissues of dogs with spontaneous distemper. Vet Immunol Immunopathol. 2000; 73: 83–98. PMID: 10678401

61. Pierrezan F, Mansell J, Ambrus A, Rodrigues Hoffmann A. Immunohistochemical expression of ionized calcium binding adapter molecule 1 in cutaneous histiocytic proliferative, neoplastic and inflammatory disorders of dogs and cats. J Comp Pathol. 2014; 151: 347–351. https://doi.org/10.1016/j.jcpa.2014.07.003 PMID: 25172051

62. Stein VM, Schreiner NM, Moore PF, Vandevenelle M, Zurbriggen A, Tipold A. Immunophenotypical characterization of monocytes in canine distemper virus infection. Vet Microbiol. 2008; 131: 237–246. https://doi.org/10.1016/j.vetmic.2008.03.009 PMID: 18472370

63. Heinrich F, Contioso VB, Stein VM, Carlson R, Tipold A, Ulrich R, et al. Passage-dependent morphological and phenotypical changes of a canine histiocytic sarcoma cell line (DH82 cells). Vet Immunol Immunopathol. 2015; 163: 86–92. https://doi.org/10.1016/j.vetimm.2014.11.006 PMID: 25534080

64. Aguin M, Houbert N, Fardel O, LeCureur V. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. Cell Immunol. 2013; 281: 51–61. https://doi.org/10.1016/j.cellimm.2013.01.010 PMID: 23454681

65. Vogel DY, Vereynen EJ, Gilme JE, Heijnen PD, Moeton M, van der Valk P, et al. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation. 2013; 10: 35. https://doi.org/10.1186/1742-2094-10-35 PMID: 23452918

66. Genin M, Clement F, Fattaccioli A, Raes M, Michiels C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer. 2015; 15: 577. https://doi.org/10.1186/s12885-015-1546-9 PMID: 26253167

67. Schwartz Y, Svistelnik AV. Functional phenotypes of macrophages and the M1-M2 polarization concept. Part I. Proinflammatory phenotype. Biochemistry (Moscow). 2012; 77: 247–260.

68. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010; 32: 593–604. https://doi.org/10.1016/j.immuni.2010.05.007 PMID: 20510870

69. Raes G, Van den Bergh R, De Baetselier P, Ghassabeh GH, Scoton C, Locati M, et al. Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J Immunol. 2005; 174: 6561; author reply 6561–6562. PMID: 15905489

70. Stoger JL, Gijbels MJ, van der Velden S, Manca M, van der Loos CM, Biessen EA, et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis. 2012; 225: 461–468. https://doi.org/10.1016/j.atherosclerosis.2012.09.013 PMID: 23078881

71. Doyle AG, Herbein G, Montaner LJ, Minty AJ, Caput D, Ferrara P, et al. Interleukin-13 alters the activation state of murine macrophages in vitro: comparison with interleukin-4 and interferon-gamma. Eur J Immunol. 1994; 24: 1441–1445. https://doi.org/10.1002/eji.1830240630 PMID: 7911424

72. Estko M, Baumgärtner S, Urech K, Kunz M, Regueiro U, Heusser P, et al. Tumour cell derived effects on monocyte/macrophage polarization and function and modulatory potential of Viscum album lipophilic extract in vitro. BMC Complement Altern Med. 2015; 15: 130. https://doi.org/10.1186/s12906-015-0650-3 PMID: 25902944

73. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992; 176: 287–292. PMID: 1613462

74. te Velde AA, Klomp JP, Yard BA, de Vries JE, Figdor CG. Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4. J Immunol. 1988; 140: 1548–1554. PMID: 3279117

75. Litman BH, Dastvan FF, Carlson PL, Sanders KM. Regulation of monocyte/macrophage C2 production and HLA-DR expression by IL-4 (BSF-1) and IFN-gamma. J Immunol. 1989; 142: 520–525. PMID: 2492049

76. Mia S, Warnecke A, Zhang XM, Malmstrom V, Harris RA. An optimized protocol for human M2 macrophages using M-CSF and IL-4/IL-10/TGF-beta yields a dominant immunosuppressive phenotype. Scand J Immunol. 2014; 79: 305–314. https://doi.org/10.1111/sji.12162 PMID: 24521472
77. Wallner S, Grandl M, Konovalova T, Sigruner A, Kopf T, Peer M, et al. Monocyte to macrophage differentiation goes along with modulation of the plasmalogen pattern through transcriptional regulation. PLoS One. 2014; 9: e94102. https://doi.org/10.1371/journal.pone.0094102 PMID: 24714687

78. Tugal D, Liao X, Jain MK. Transcriptional control of macrophage polarization. Arterioscler Thromb Vasc Biol. 2013; 33: 1135–1144. https://doi.org/10.1161/ATVBAHA.113.301453 PMID: 23640482

79. Bouhlel MA, Derudas B, Rigamonti E, Dievart J, Haulon S, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007; 6: 137–143. https://doi.org/10.1016/j.cmet.2007.06.010 PMID: 17681149

80. Chawla A. Control of macrophage activation and function by PPARs. Circ Res. 2010; 106: 1559–1569. https://doi.org/10.1161/CIRCRESAHA.110.216523 PMID: 20508200

81. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function. Curr Opin Lipidol. 2003; 14: 459–468. https://doi.org/10.1097/01.mol.0000092630.86399.00 PMID: 14501584

82. Zizzo G, Cohen PL. The PPAR-gamma antagonist GW9662 elicits differentiation of M2c-like cells and upregulation of the MerTK/Gas6 axis: a key role for PPAR-gamma in human macrophage polarization. J Inflamm (Lond). 2015; 12: 36.

83. Hong G, Davis B, Khatoon N, Baker SF, Brown J. PPAR gamma-dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNF alpha secretion is not mediated by PTEN regulation. Biochem Biophys Res Commun. 2003; 303: 782–787. PMID: 12670479

84. Lefevre L, Gales A, Olagnier D, Bernard J, Perez L, Burcelin R, et al. PPARgamma ligands switched high fat diet-induced macrophage M2b polarization toward M2a thereby improving intestinal Candida elimination. PLoS One. 2010; 5: e12828. https://doi.org/10.1371/journal.pone.0012828 PMID: 20877467

85. Aagaard A, Listwan P, Cowieson N, Huber T, Ravasi T, Wells CA, et al. An inflammatory role for the mammalian carboxypeptidase inhibitor latexin: relationship to cystatins and the tumor suppressor TIG1. Structure. 2005; 13: 309–317. https://doi.org/10.1016/j.str.2004.12.013 PMID: 15698574

86. Arimatsu Y, Ishida M, Sato M, Kojima M. Corticocortical associative neurons expressing latexin: specific cortical connectivity formed in vivo and in vitro. Cereb Cortex. 1999; 9: 569–576. PMID: 10498275

87. Arimatsu Y. Latexin: a molecular marker for regional specification in the neocortex. Neurosci Res. 1994; 20: 131–135. PMID: 7808696

88. Takiguchi-Hayashi K, Sato M, Sugo N, Ishida M, Sato K, Uratani Y, et al. Latexin expression in smaller diameter primary sensory neurons in the rat. Brain Res. 1998; 801: 9–20. PMID: 9729242

89. Cao L, He C. Polarization of macrophages and microglia in inflammatory demyelination. Neurosci Bull. 2013; 29: 189–198. https://doi.org/10.1007/s12264-013-1324-0 PMID: 23558588